BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 9235296)

  • 1. Is there a future for PET in oncology?
    Price P
    Eur J Nucl Med; 1997 Jun; 24(6):587-9. PubMed ID: 9235296
    [No Abstract]   [Full Text] [Related]  

  • 2. Does fluorine-18 fluorodeoxyglucose metabolic imaging of tumours benefit oncology?
    Brock CS; Meikle SR; Price P
    Eur J Nucl Med; 1997 Jun; 24(6):691-705. PubMed ID: 9169580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Diagnosis of cancers by FDG-PET].
    Ichiya Y
    Fukuoka Igaku Zasshi; 1997 Jan; 88(1):7-10. PubMed ID: 9091463
    [No Abstract]   [Full Text] [Related]  

  • 4. Positron emission tomographic oncology.
    Lawson MA
    West J Med; 1994 Oct; 161(4):411-2. PubMed ID: 7817554
    [No Abstract]   [Full Text] [Related]  

  • 5. PET cancer evaluations with FDG.
    Hawkins RA; Hoh C; Dahlbom M; Choi Y; Glaspy J; Tse N; Slamon D; Chen B; Messa C; Maddahi J
    J Nucl Med; 1991 Aug; 32(8):1555-8. PubMed ID: 1869978
    [No Abstract]   [Full Text] [Related]  

  • 6. Positron emission tomography in oncology. General acceptance of its role is overdue.
    Lamki LM
    Cancer; 1996 Nov; 78(10):2039-42. PubMed ID: 8918394
    [No Abstract]   [Full Text] [Related]  

  • 7. [Use of positron-emission tomography in oncology].
    Strauss LG; Kabelitz D; Kremer B; Lode H; Meinertz T; Sauerbruch T; Sterry W
    Dtsch Med Wochenschr; 1996 Feb; 121(7):207-9. PubMed ID: 8681765
    [No Abstract]   [Full Text] [Related]  

  • 8. Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose.
    Rigo P; Paulus P; Kaschten BJ; Hustinx R; Bury T; Jerusalem G; Benoit T; Foidart-Willems J
    Eur J Nucl Med; 1996 Dec; 23(12):1641-74. PubMed ID: 8929320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proceedings of a National Cancer Institute workshop: PET in oncology--a clinical research agenda.
    Wahl RL; Hawkins RA; Larson SM; Hendee WR; Coleman RE; Holden RW; Frick MP; Gatsonis C; Brown GS; Shtern F
    Radiology; 1994 Dec; 193(3):604-6. PubMed ID: 7972793
    [No Abstract]   [Full Text] [Related]  

  • 10. PET and [18F]-FDG in oncology: a clinical update.
    Conti PS; Lilien DL; Hawley K; Keppler J; Grafton ST; Bading JR
    Nucl Med Biol; 1996 Aug; 23(6):717-35. PubMed ID: 8940714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer treatment monitoring with fluorine-18 2-fluoro-2-deoxy-D-glucose and positron emission tomography: frustration or future.
    Minn H; Paul R
    Eur J Nucl Med; 1992; 19(11):921-4. PubMed ID: 1425778
    [No Abstract]   [Full Text] [Related]  

  • 12. Cancer or inflammation? A Holy Grail for nuclear medicine.
    Larson SM
    J Nucl Med; 1994 Oct; 35(10):1653-5. PubMed ID: 7931666
    [No Abstract]   [Full Text] [Related]  

  • 13. Positron emission tomography in oncology.
    Leskinen-Kallio S
    Clin Physiol; 1994 May; 14(3):329-35. PubMed ID: 8026150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone scanning in clinical oncology: does it have a future?
    Jacobson AF; Fogelman I
    Eur J Nucl Med; 1998 Sep; 25(9):1219-23. PubMed ID: 9724368
    [No Abstract]   [Full Text] [Related]  

  • 15. SUV: standard uptake or silly useless value?
    Keyes JW
    J Nucl Med; 1995 Oct; 36(10):1836-9. PubMed ID: 7562051
    [No Abstract]   [Full Text] [Related]  

  • 16. Fluorodeoxyglucose (FDG) and tumour metabolism.
    Van Wyngaarden KE; Pauwels EK
    Nucl Med Commun; 1995 Dec; 16(12):987-9. PubMed ID: 8719978
    [No Abstract]   [Full Text] [Related]  

  • 17. PET with fluorine-18 deoxyglucose for pancreatic disease.
    Klever P; Bares R; Fass J; Büll U; Schumpelick V
    Lancet; 1992 Nov; 340(8828):1158-9. PubMed ID: 1359226
    [No Abstract]   [Full Text] [Related]  

  • 18. Is there a role for FDG PET imaging in the management of patients with sarcoidosis?
    Alavi A; Buchpiguel CA; Loessner A
    J Nucl Med; 1994 Oct; 35(10):1650-2. PubMed ID: 7931665
    [No Abstract]   [Full Text] [Related]  

  • 19. Triple-head SPECT with 2-[fluorine-18]fluoro-2-deoxy-D-glucose (FDG): initial evaluation in oncology and comparison with FDG PET.
    Macfarlane DJ; Cotton L; Ackermann RJ; Minn H; Ficaro EP; Shreve PD; Wahl RL
    Radiology; 1995 Feb; 194(2):425-9. PubMed ID: 7824722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cancer diagnosis with positron emission tomography (PET)].
    Kubota K
    Kaku Igaku; 1996 Feb; 33(2):207-12. PubMed ID: 8721109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.